European Regulators Broaden Pepaxti Approval for Multiple Myeloma Treatment

The European Commission has expanded the marketing authorization for Pepaxti (melflufen), a multiple myeloma drug, to include adult patients who have undergone at least two prior lines of therapy. This decision elevates Pepaxti to a third-line treatment option and removes the previous requirement for patients to be refractory to three major myeloma classes. This change is expected to significantly increase the eligible patient population in Europe.